Healthcare / BiotechnologyBSE
$109.10
-0.90 (-0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-35.2M · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
88.0x
↑EV/EBITDA
63.5x
↑ROE
15.3%
↑Gross Margin
7.4%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+493.5%
FCF CAGR
+105.4%
FCF margin
1.3%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $363.2M · net income $18.1M · FCF $4.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $363.2M | $363.2M | $190.5M | $57.9M | $1.7M |
| Net Income | $18.1M | $18.1M | $10.2M | $827629.00 | $410464.00 |
| EBITDA | $25.0M | $25.0M | $12.6M | $1.1M | $554904.00 |
| EPS | — | — | 0.70 | 0.09 | 0.05 |
| Gross Margin | 7.4% | 7.4% | 6.7% | 6.7% | 11.5% |
| Operating Margin | 6.4% | 6.4% | 5.6% | 0.8% | -216.1% |
| Net Margin | 5.0% | 5.0% | 5.3% | 1.4% | 23.6% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | -0.73 |
| Current Ratio | 0.47 | 0.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.6M | $4.6M | $-35.2M | $-60.3M | $526036.00 |
| Returns | |||||
| ROE | 15.3% | 15.3% | 10.2% | 1.0% | -4.9% |
| Valuation | |||||
| P/E | 87.98 | 87.98 | 37.14 | 97.11 | 152.00 |
| EV/EBITDA | 63.55 | 63.55 | 30.07 | 48.42 | 76.94 |
| P/B | 13.51 | 13.51 | 3.77 | 0.94 | — |
| Growth & Yield | |||||
| Revenue Growth | 90.7% | 90.7% | 229.0% | 3231.1% | — |
| EPS Growth | — | — | 677.8% | 80.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+315.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.70 → n/d
Residual
+315.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.